Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.

Gray GE, Huang Y, Grunenberg N, Laher F, Roux S, Andersen-Nissen E, De Rosa SC, Flach B, Randhawa AK, Jensen R, Swann EM, Bekker LG, Innes C, Lazarus E, Morris L, Mkhize NN, Ferrari G, Montefiori DC, Shen X, Sawant S, Yates N, Hural J, Isaacs A, Phogat S, DiazGranados CA, Lee C, Sinangil F, Michael NL, Robb ML, Kublin JG, Gilbert PB, McElrath MJ, Tomaras GD, Corey L.

Sci Transl Med. 2019 Sep 18;11(510). pii: eaax1880. doi: 10.1126/scitranslmed.aax1880.

PMID:
31534016
2.

Daily Vaginal Swabs and Mobile Phone Sex Report for Assessing HIV Virion Exposure Prospectively Among a Cohort of Young Sexually Active Women in South Africa (HVTN 915).

Lemos MP, Lazarus E, Isaacs A, Dietrich J, Morgan C, Huang Y, Grove D, Andrasik M, Laher F, Hural J, Chung E, Dragavon J, Puren A, Gulati RK, Coombs R, McElrath MJ, Gray G, Kublin JG.

J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):e39-e48. doi: 10.1097/QAI.0000000000002015.

PMID:
31095007
3.

Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period.

Spearman P, Tomaras GD, Montefiori DC, Huang Y, Elizaga ML, Ferrari G, Alam SM, Isaacs A, Ahmed H, Hural J, McElrath MJ, Ouedraogo L, Pensiero M, Butler C, Kalams SA, Overton ET, Barnett SW; HVTN 088 Protocol Team and the NIH/NIAID HIV Vaccine Trials Network.

J Infect Dis. 2019 May 5;219(11):1755-1765. doi: 10.1093/infdis/jiz008.

PMID:
30615119
4.

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.

Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, Donnell DJ, Bentley C, Sista N, Andrew P, Isaacs A, Huang Y, Zhang L, Capparelli E, Kochar N, Wang J, Eshleman SH, Mayer KH, Magaret CA, Hural J, Kublin JG, Gray G, Montefiori DC, Gomez MM, Burns DN, McElrath J, Ledgerwood J, Graham BS, Mascola JR, Cohen M, Corey L.

Stat Commun Infect Dis. 2017 Jan;9(1). pii: 20160001. doi: 10.1515/scid-2016-0001. Epub 2017 Jun 6.

5.

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.

Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, Ledgerwood JE, Frank I, Sobieszczyk ME, Baden LR, Rodriguez B, Van Tieu H, Tomaras GD, Deal A, Goodman D, Bailer RT, Ferrari G, Jensen R, Hural J, Graham BS, Mascola JR, Corey L, Montefiori DC; HVTN 104 Protocol Team; and the NIAID HIV Vaccine Trials Network.

PLoS Med. 2017 Nov 14;14(11):e1002435. doi: 10.1371/journal.pmed.1002435. eCollection 2017 Nov.

6.

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.

Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R, Finak G, Grove D, Shen M, Graham BS, Koup RA, Mulligan MJ, Koblin B, Buchbinder SP, Keefer MC, Adams E, Anude C, Corey L, Sobieszczyk M, Hammer SM, Gilbert PB, McElrath MJ.

J Infect Dis. 2017 May 1;215(9):1376-1385. doi: 10.1093/infdis/jix086.

7.

Functions of IL-4 and Control of Its Expression.

Brown MA, Hural J.

Crit Rev Immunol. 2017;37(2-6):181-212. doi: 10.1615/CritRevImmunol.v37.i2-6.30. Review.

PMID:
29773020
8.

A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.

Hertz T, Logan MG, Rolland M, Magaret CA, Rademeyer C, Fiore-Gartland A, Edlefsen PT, DeCamp A, Ahmed H, Ngandu N, Larsen BB, Frahm N, Marais J, Thebus R, Geraghty D, Hural J, Corey L, Kublin J, Gray G, McElrath MJ, Mullins JI, Gilbert PB, Williamson C.

Vaccine. 2016 Nov 11;34(47):5792-5801. doi: 10.1016/j.vaccine.2016.09.054. Epub 2016 Oct 15.

9.

The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.

Jacobson JM, Zheng L, Wilson CC, Tebas P, Matining RM, Egan MA, Eldridge J, Landay AL, Clifford DB, Luetkemeyer AF, Tiu J, Martinez AL, Janik J, Spitz TA, Hural J, McElrath J, Frahm N; ACTG A5281 Protocol Team.

J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):163-71. doi: 10.1097/QAI.0000000000000830.

10.

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, Li F, Hertz T, Self SG, Friedrich D, Frahm N, Liao HX, Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X; HVTN 083 Study Group and the NIAID HVTN.

J Infect Dis. 2016 Feb 15;213(4):541-50. doi: 10.1093/infdis/jiv496. Epub 2015 Oct 15.

11.

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders.

Janes H, Herbeck JT, Tovanabutra S, Thomas R, Frahm N, Duerr A, Hural J, Corey L, Self SG, Buchbinder SP, McElrath MJ, O'Connell RJ, Paris RM, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, Robb ML, Michael NL, Mullins JI, Kim JH, Gilbert PB, Rolland M.

Nat Med. 2015 Oct;21(10):1139-41. doi: 10.1038/nm.3932. Epub 2015 Aug 31.

12.

HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians.

VISR Working Group of Global HIV Vaccine Enterprise, Voronin Y, Zinszner H, Karg C, Brooks K, Coombs R, Hural J, Holt R, Fast P, Allen M.

Vaccine. 2015 Mar 3;33(10):1243-9. doi: 10.1016/j.vaccine.2014.10.040. Epub 2015 Jan 31. Review.

13.

HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.

Bart PA, Huang Y, Karuna ST, Chappuis S, Gaillard J, Kochar N, Shen X, Allen MA, Ding S, Hural J, Liao HX, Haynes BF, Graham BS, Gilbert PB, McElrath MJ, Montefiori DC, Tomaras GD, Pantaleo G, Frahm N.

J Clin Invest. 2014 Nov;124(11):4843-56. doi: 10.1172/JCI75894. Epub 2014 Oct 1.

14.

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.

Frey SE, Peiperl L, McElrath MJ, Kalams S, Goepfert PA, Keefer MC, Baden LR, Lally MA, Mayer K, Blattner WA, Harro CD, Hammer SM, Gorse GJ, Hural J, Tomaras GD, Levy Y, Gilbert P, deCamp A, Russell ND, Elizaga M, Allen M, Corey L.

Clin Vaccine Immunol. 2014 Nov;21(11):1589-99. doi: 10.1128/CVI.00450-14. Epub 2014 Sep 24.

15.

Benefits of a comprehensive quality program for cryopreserved PBMC covering 28 clinical trials sites utilizing an integrated, analytical web-based portal.

Ducar C, Smith D, Pinzon C, Stirewalt M, Cooper C, McElrath MJ, Hural J; NIAID HIV Vaccine Trials Network.

J Immunol Methods. 2014 Jul;409:9-20. doi: 10.1016/j.jim.2014.03.024. Epub 2014 Apr 4.

16.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, DeRosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, Buchbinder SP, Hammer SM, Koblin BA, Pensiero M, Butler C, Moss B, Robinson HL; HVTN 205 Study Group; National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network.

J Infect Dis. 2014 Jul 1;210(1):99-110. doi: 10.1093/infdis/jiu003. Epub 2014 Jan 7.

17.

Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants.

Penezina O, Krueger NX, Rodriguez-Chavez IR, Busch MP, Hural J, Kim JH, O'Connell RJ, Hunter E, Aboud S, Higgins K, Kovalenko V, Clapham D, Crane D, Levin AE; HIV Selectest Study Group.

Clin Vaccine Immunol. 2014 Mar;21(3):391-8. doi: 10.1128/CVI.00748-13. Epub 2014 Jan 8.

18.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB; HVTN 505 Study Team.

N Engl J Med. 2013 Nov 28;369(22):2083-92. doi: 10.1056/NEJMoa1310566. Epub 2013 Oct 7.

19.

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, Fuchs J, Koblin B, Kim DH, Joseph P, Keefer MC, Baden LR, Eldridge J, Boyer J, Sherwat A, Cardinali M, Allen M, Pensiero M, Butler C, Khan AS, Yan J, Sardesai NY, Kublin JG, Weiner DB; NIAID HIV Vaccine Trials Network.

J Infect Dis. 2013 Sep 1;208(5):818-29. doi: 10.1093/infdis/jit236. Epub 2013 Jul 8.

20.

Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.

Wecker M, Gilbert P, Russell N, Hural J, Allen M, Pensiero M, Chulay J, Chiu YL, Abdool Karim SS, Burke DS; HVTN 040/059 Protocol Team; NIAID HIV Vaccine Trials Network.

Clin Vaccine Immunol. 2012 Oct;19(10):1651-60. Epub 2012 Aug 22.

21.

Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.

Cheng C, Wang L, Gall JG, Nason M, Schwartz RM, McElrath MJ, DeRosa SC, Hural J, Corey L, Buchbinder SP, Nabel GJ.

PLoS One. 2012;7(4):e33969. doi: 10.1371/journal.pone.0033969. Epub 2012 Apr 4. Erratum in: PLoS One. 2012;7(5): doi/10.1371/annotation/805c32e9-70cf-4937-af15-e26de6a11e99. Wang, LingShu [corrected to Wang, Lingshu]..

22.

Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials.

Stephenson KE, Hural J, Buchbinder SP, Sinangil F, Barouch DH.

J Infect Dis. 2012 Jun 15;205(12):1806-10. doi: 10.1093/infdis/jis285. Epub 2012 Apr 5.

23.

Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults.

Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, Hural J, Lubeck M, Eldridge J, Cardinali M, Blattner WA, Sobieszczyk M, Suriyanon V, Kalichman A, Weiner DB, Baden LR; NIAID HIV Vaccine Trials Network.

PLoS One. 2012;7(1):e29231. doi: 10.1371/journal.pone.0029231. Epub 2012 Jan 5.

24.

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).

Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M, Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network.

PLoS One. 2011;6(8):e21225. doi: 10.1371/journal.pone.0021225. Epub 2011 Aug 3.

25.

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.

Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P, Sinangil F, de Bruyn G, Gray GE, Roux S, Bekker LG, Dilraj A, Kibuuka H, Robb ML, Michael NL, Anzala O, Amornkul PN, Gilmour J, Hural J, Buchbinder SP, Seaman MS, Dolin R, Baden LR, Carville A, Mansfield KG, Pau MG, Goudsmit J.

Vaccine. 2011 Jul 18;29(32):5203-9. doi: 10.1016/j.vaccine.2011.05.025. Epub 2011 May 25.

26.

A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.

Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, McElrath MJ, Hural J, De Rosa SC, Sato A, Huang Y, Frey SE, Sato P, Donnelly J, Barnett S, Corey LJ; HIV Vaccine Trials Network of NIAID.

J Infect Dis. 2011 Apr 15;203(8):1165-73. doi: 10.1093/infdis/jiq175.

27.

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.

Rolland M, Tovanabutra S, deCamp AC, Frahm N, Gilbert PB, Sanders-Buell E, Heath L, Magaret CA, Bose M, Bradfield A, O'Sullivan A, Crossler J, Jones T, Nau M, Wong K, Zhao H, Raugi DN, Sorensen S, Stoddard JN, Maust BS, Deng W, Hural J, Dubey S, Michael NL, Shiver J, Corey L, Li F, Self SG, Kim J, Buchbinder S, Casimiro DR, Robertson MN, Duerr A, McElrath MJ, McCutchan FE, Mullins JI.

Nat Med. 2011 Mar;17(3):366-71. doi: 10.1038/nm.2316. Epub 2011 Feb 27.

28.

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, DeRosa SC, DeFawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, Frey SE, Blattner WA, Wyatt LS, Moss B, Robinson HL; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network.

J Infect Dis. 2011 Mar 1;203(5):610-9. doi: 10.1093/infdis/jiq105. Epub 2011 Jan 31.

29.

Equivalence of ELISpot assays demonstrated between major HIV network laboratories.

Gill DK, Huang Y, Levine GL, Sambor A, Carter DK, Sato A, Kopycinski J, Hayes P, Hahn B, Birungi J, Tarragona-Fiol T, Wan H, Randles M, Cooper AR, Ssemaganda A, Clark L, Kaleebu P, Self SG, Koup R, Wood B, McElrath MJ, Cox JH, Hural J, Gilmour J.

PLoS One. 2010 Dec 14;5(12):e14330. doi: 10.1371/journal.pone.0014330.

30.

Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays.

Weinberg A, Song LY, Wilkening CL, Fenton T, Hural J, Louzao R, Ferrari G, Etter PE, Berrong M, Canniff JD, Carter D, Defawe OD, Garcia A, Garrelts TL, Gelman R, Lambrecht LK, Pahwa S, Pilakka-Kanthikeel S, Shugarts DL, Tustin NB.

J Immunol Methods. 2010 Dec 15;363(1):42-50. doi: 10.1016/j.jim.2010.09.032. Epub 2010 Oct 1.

31.

Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials.

Sarzotti-Kelsoe M, Cox J, Cleland N, Denny T, Hural J, Needham L, Ozaki D, Rodriguez-Chavez IR, Stevens G, Stiles T, Tarragona-Fiol T, Simkins A.

PLoS Med. 2009 May 26;6(5):e1000067. doi: 10.1371/journal.pmed.1000067. Epub 2009 May 5. No abstract available.

32.

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR; Step Study Protocol Team.

Lancet. 2008 Nov 29;372(9653):1894-1905. doi: 10.1016/S0140-6736(08)61592-5. Epub 2008 Nov 13.

33.

Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials.

Moodie Z, Huang Y, Gu L, Hural J, Self SG.

J Immunol Methods. 2006 Aug 31;315(1-2):121-32. Epub 2006 Aug 15.

PMID:
16959262
34.

Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation.

Hural JA, Friedman RS, McNabb A, Steen SS, Henderson RA, Kalos M.

J Immunol. 2002 Jul 1;169(1):557-65.

35.

An intron transcriptional enhancer element regulates IL-4 gene locus accessibility in mast cells.

Hural JA, Kwan M, Henkel G, Hock MB, Brown MA.

J Immunol. 2000 Sep 15;165(6):3239-49.

36.

Functions of IL-4 and control of its expression.

Brown MA, Hural J.

Crit Rev Immunol. 1997;17(1):1-32. Review.

PMID:
9034722
37.

Nuclear factor of activated T cells is associated with a mast cell interleukin 4 transcription complex.

Weiss DL, Hural J, Tara D, Timmerman LA, Henkel G, Brown MA.

Mol Cell Biol. 1996 Jan;16(1):228-35.

38.

The estimation of dihydropteridine reductase in human blood cells.

Webber S, Hural JA, Whiteley JM.

Clin Chim Acta. 1988 Apr 15;173(2):117-26.

PMID:
3378353
39.

Structural studies and isolation of cDNA clones providing the complete sequence of rat liver dihydropteridine reductase.

Shahbaz M, Hoch JA, Trach KA, Hural JA, Webber S, Whiteley JM.

J Biol Chem. 1987 Dec 5;262(34):16412-6.

40.

Preliminary studies on the primary structure of rat liver dihydropteridine reductase.

Webber S, Hural J, Whiteley JM.

Biochem Biophys Res Commun. 1987 Mar 13;143(2):582-6.

PMID:
3566737
41.

Multiple forms of rat-liver dihydropteridine reductase identified by their differing isoelectric points.

Webber S, Hural JA, Whiteley JM.

Arch Biochem Biophys. 1986 Jul;248(1):358-67.

PMID:
3729422

Supplemental Content

Support Center